Nuwellis Inc
NASDAQ:NUWE
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.1800
  • TODAY'S CHANGE (%)
    -0.0260 (-12.6214%)
  • Bid / Lots
    0.1705/ 10
  • Ask / Lots
    0.1820/ 15
  • Open / Previous Close
    0.2150 / 0.2060
  • Day Range
    0.1674
    0.2320
  • 52 Week Range
    0.1250
    4.7800
  • Volume
    10,920,826

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • May 2, 2024

      Show headlines and story abstract

    • 9:00AM ET on Thursday May 02, 2024 by Dow Jones
      Companies Mentioned: NUWE

      Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

      MINNEAPOLIS, May 02, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application related to its innovative pediatric Continuous Renal Replacement Therapy (CRRT) device branded Vivian(TM). This patent strengthens Nuwellis' intellectual property portfolio and paves the way for the development of novel technology designed to improve treatment options for critically ill children.

  • Apr 30, 2024

      Show headlines and story abstract

    • 6:09PM ET on Tuesday Apr 30, 2024 by Dow Jones
      Companies Mentioned: NUWE

      Nuwellis Announces Closing of $2.7 Million Public Offering

      MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) ("Nuwellis" or the "Company"), a medical technology company focused on transforming the lives of people with fluid overload, today announced the closing of its previously announced public offering of 11,250,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 16,875,000 shares of its common stock at a combined public offering price of $0.24 per share (or pre-funded warrant in lieu thereof) and associated warrant. Each share of common stock (or prefunded warrant in lieu thereof) was sold together with one warrant to purchase one and a half shares of common stock. The warrants have an exercise price of $0.40 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance.

    • 4:41PM ET on Tuesday Apr 30, 2024 by Dow Jones
      Companies Mentioned: NUWE

      Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024

      MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter of 2024 on Tuesday, May 7, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.

  • Apr 29, 2024

  • Apr 26, 2024

      Show headlines and story abstract

    • 9:17AM ET on Friday Apr 26, 2024 by Dow Jones
      Companies Mentioned: NUWE

      Nuwellis Announces Pricing of $2.7 Million Public Offering

      MINNEAPOLIS, April 26, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) ("Nuwellis" or the "Company"), a medical technology company focused on transforming the lives of people with fluid overload, today announced the pricing of a public offering of 11,250,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 16,875,000 shares of its common stock at a combined public offering price $0.24 per share (or pre-funded warrant in lieu thereof) and associated warrant. Each share of common stock (or prefunded warrant in lieu thereof) is being sold together with one warrant to purchase one and a half shares of common stock. The warrants will have an exercise price of $0.40 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance.

Peers Headlines